Session » (0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

Date: Sunday, November 12, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 0665

A Descriptive Study of Disease Characterisics of SSc Patients with the U2RNP Autoantibody

9:00AM-11:00AM: Abstract Number: 0632

A Longitudinal Analysis of Mouth Opening in 1101 Systemic Sclerosis Patients from the French National Cohort Study

9:00AM-11:00AM: Abstract Number: 0655

A Novel Association Between Lipodermatosclerosis and Key Vascular Outcomes in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0651

Abnormal Nailfold Video-capillaroscopy Is Independently Associated with non-UIP Radiographic Patterns in Autoimmune ILD: A Multicenter Study from the NEREA Registry

9:00AM-11:00AM: Abstract Number: 0638

Application of the 2022 European Society of Cardiology (ESC) Risk Assessment Model in Australian and Singaporean Systemic Sclerosis Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH)

9:00AM-11:00AM: Abstract Number: 0661

Assessment of Systemic Sclerosis-Associated Myocarditis: A Single Center Case Series Study

9:00AM-11:00AM: Abstract Number: 0653

Association Between Systemic Sclerosis and Increased Risk of Ischemic Stroke: A Meta-Analysis

9:00AM-11:00AM: Abstract Number: 0662

Changes in Treatment Patterns and Their Influence on the Outcome of Systemic Sclerosis-interstitial Lung Disease (SSc-ILD) Patients: An EUSTAR Analysis

9:00AM-11:00AM: Abstract Number: 0636

Chasing Pain: Investigating Somatosensory Profiles in Patients with Rheumatological Diseases Using Quantitative Sensory Testing

9:00AM-11:00AM: Abstract Number: 0659

Cigarette Exposure in Systemic Sclerosis: Impact on Autoantibody Expression and Disease Manifestations: Analysis of the EUSTAR Cohort

9:00AM-11:00AM: Abstract Number: 0660

Cigarette Smoking Increases the Risk of All-Cause Mortality in Male Patients with Systemic Sclerosis: An Analysis of the EUSTAR Cohort

9:00AM-11:00AM: Abstract Number: 0635

Clinical Characteristics and Longitudinal Outcomes of Patients with Childhood-Onset Systemic Sclerosis at a Tertiary Center

9:00AM-11:00AM: Abstract Number: 0642

Clinical Characteristics of Systemic Sclerosis, Systemic Sclerosis Overlap Syndromes and Systemic Sclerosis-mixed Connective Tissue Disease in an Asia-Pacific Cohort- an APLAR Scleroderma Special Interest Group Study

9:00AM-11:00AM: Abstract Number: 0626

Clinical Features of Anti-hUBF Antibodies-positive Patients: A Single-center Retrospective Study

9:00AM-11:00AM: Abstract Number: 0627

Clinical Significance of Anti-Ro/SSA Antibodies in Patients with Systemic Sclerosis: A Study from the EUSTAR Database

9:00AM-11:00AM: Abstract Number: 0654

Comparison of Cardiovascular Risk in Patients with Systemic Sclerosis and the General Population

9:00AM-11:00AM: Abstract Number: 0637

Comparison of Four Risk Stratification Models for Prediction of Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in the EUSTAR Cohort

9:00AM-11:00AM: Abstract Number: 0656

Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression

9:00AM-11:00AM: Abstract Number: 0645

Continuous Progressive ILD in Systemic Sclerosis Is Associated with Mortality

9:00AM-11:00AM: Abstract Number: 0612

COVID Vaccinations and Infections Among Individuals with Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study

9:00AM-11:00AM: Abstract Number: 0671

Decreased Odds of Malignancy with Mycophenolate Use in a Single-Center Scleroderma Cohort

9:00AM-11:00AM: Abstract Number: 0611

Demographics and Clinical Features Associated with Small Bowel Hypomotility in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0619

Different Definitions of Disease Severity, Progression and Outcomes in Systemic Sclerosis Associated Interstitial Lung Disease: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 0616

Does Systemic Sclerosis Affect the Interpretation of Mammograms? A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 0649

Early Systemic Sclerosis Definitions: Time to Rethink ‘Early’ in SSc Disease?

9:00AM-11:00AM: Abstract Number: 0652

Ethnic Variations in Systemic Sclerosis Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 0639

Evaluating Esophageal Dysmotility by Scintigraphy in Systemic Sclerosis: Subsets and Phenotypes

9:00AM-11:00AM: Abstract Number: 0658

Evaluating the Associations Between Autonomic Dysfunction, Clinical Phenotype and Gastrointestinal Transit in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0648

Incidence and Prevalence of Malnutrition and Its Impact on Mortality in the Multicentre Singapore Systemic Sclerosis Cohort

9:00AM-11:00AM: Abstract Number: 0618

Incident versus Prevalent Interstitial Lung Disease in Systemic Sclerosis in the EUSTAR Database: Different Disease Phenotypes and Prognosis

9:00AM-11:00AM: Abstract Number: 0668

Increased Risk of Cancer in Patients with Systemic Sclerosis: A Population-based Study

9:00AM-11:00AM: Abstract Number: 0628

Interstitial Lung Disease in Very Early Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0609

Mortality After Autologous Hematopoietic Stem Cell Transplant for Autoimmune Disease: Do Scleroderma Patients Fare Worse?

9:00AM-11:00AM: Abstract Number: 0640

Multidisciplinary and Multiparametric Evaluation of Sarcopenia in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0610

Nailfold Capillaroscopy for Prediction of Novel Severe Organ Involvement in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0623

Nailfold Capillaroscopy in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib

9:00AM-11:00AM: Abstract Number: 0629

Negative Affect, Anxiety and Fatigue Moderate the Association Between Pain Intensity and Physical Function in People with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0669

Optical Coherence Tomography Angiography in Systemic Sclerosis: Correlations with Morphological and Functional Peripheral Microvascular Status

9:00AM-11:00AM: Abstract Number: 0624

Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Based on Serological Profiles: Focus on Anti-Centromere Antibody (ACA) and Anti-RNA Polymerase III (ARA) Antibodies

9:00AM-11:00AM: Abstract Number: 0620

Physical and Mental Health in Early Systemic Sclerosis: Baseline Results for Patient-Reported Outcomes Measurement Information System-29 from the Collaborative National Quality and Efficacy Registry

9:00AM-11:00AM: Abstract Number: 0633

Prediction of Progressive Fibrosing Interstitial Lung Disease in Systemic Sclerosis Patients: Insight from the CRDC Cohort Study

9:00AM-11:00AM: Abstract Number: 0644

Prediction of Stable SSc-ILD Depends on Definition of ILD Progression

9:00AM-11:00AM: Abstract Number: 0634

Prevalence and Associations of Anaemia in Systemic Sclerosis Patients in a National Observational Cohort; Results from the Australian Scleroderma Cohort Study

9:00AM-11:00AM: Abstract Number: 0630

Prevalence and Risk Factors for Systemic Sclerosis Digital Ischemic Complications in the Collaborative National Quality and Efficacy Registry

9:00AM-11:00AM: Abstract Number: 0647

Prevalence and Risk Factors of Left Ventricular Diastolic Dysfunction in Systemic Sclerosis: Insights from New Echocardiographic Parameters

9:00AM-11:00AM: Abstract Number: 0615

Prevalence of Barrett’s Esophagus in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0643

Progression of Interstitial Lung Disease in Systemic Sclerosis Does Not Predict Further Progression

9:00AM-11:00AM: Abstract Number: 0617

Pulmonary Rehabilitation in Connective Tissue Disease-Related Interstitial Lung Diseases

9:00AM-11:00AM: Abstract Number: 0613

Quantification of Skin Hardness of Patients with Systemic Sclerosis Using SOFTGRAM

9:00AM-11:00AM: Abstract Number: 0664

Quantitative Hand Held Dynamometry to Assess Muscle Strength in Scleroderma Associated Myopathy

9:00AM-11:00AM: Abstract Number: 0646

Racial Variability in Immune Responses Only Partially Explains Differential Systemic Sclerosis Disease Severity

9:00AM-11:00AM: Abstract Number: 0672

Risk of New-onset Depression in Patients with Systemic Sclerosis : A Nationwide Population-based Study

9:00AM-11:00AM: Abstract Number: 0631

Safety of Radiotherapy for Malignancy in Systemic Sclerosis. a Systematic Review

9:00AM-11:00AM: Abstract Number: 0621

Scleroderma Renal Crisis: A Large Single-center Experience

9:00AM-11:00AM: Abstract Number: 0614

Self-Reported Sexual Dysfunction and Perceptions of Rheumatologist Engagement on This Issue in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0622

The Effectiveness of Breath-holding Test to Predict Pulmonary Function in Systemic Sclerosis Patients Using Machine Learning Model

9:00AM-11:00AM: Abstract Number: 0641

The Evaluation of Lower Extremities Arterial Disease in Systemic Sclerosis Patients Through Rheumatologist-Vascular Surgeon Multidisciplinary Management: Preliminary Data from an Italian Single Center Study

9:00AM-11:00AM: Abstract Number: 0667

The Risk of Stroke and Myocardial Infarction in Systemic Sclerosis: A Population-based Study

9:00AM-11:00AM: Abstract Number: 0657

The Value of the Six-Minute Walk Test in Detecting Cardiopulmonary Involvement in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0670

Title: Patient Characteristics and Outcomes of Scleroderma Renal Crisis versus Hypertensive Emergencies: A Nationwide Comparative Study

9:00AM-11:00AM: Abstract Number: 0666

Troponin I Levels in Systemic Sclerosis Patients with Myocardial Involvement

9:00AM-11:00AM: Abstract Number: 0650

Understanding the Employment Landscape in People with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0625

Use of Heated Gloves for Raynaud’s Phenomenon in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0663

Vaccine-Preventable Diseases in Hospitalized Patients with Systemic Sclerosis: A Nationwide Cohort Analysis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].